The NIH halted its policy requiring universities and research institutes to certify they do not have unlawful diversity, ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Vaccination rates across the country have continued to fall since the height of the pandemic, but the coronavirus never ...

Airport screening in the United States has detected the new variant in travelers arriving from those regions to destinations ...

Moderna’s next-generation COVID-19 vaccine earns FDA approval for high-risk groups only. Learn what this could mean for ...

US Health Secretary Robert F. Kennedy Jr had earlier issued contradictory information. Read more at straitstimes.com. Read ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...